Merck's Welireg Combo Fails in First-Line Kidney Cancer
Merck reported that adding Welireg (lenvatinib) to Keytruda (pembrolizumab) did not improve outcomes for treatment‑naïve patients with advanced renal cell carcinoma. In the phase‑3 CLEAR trial, the combination failed to meet its primary progression‑free survival endpoint, showing a median of 8.3 months versus 8.0 months for pembrolizumab alone. Overall response rates were identical at 36%, and no overall‑survival benefit emerged. The setback follows earlier success of the duo in later‑line settings and challenges Merck’s first‑line strategy.
UnitedHealth Breaks Down How It Plans to Spend $1.5B on AI
UnitedHealth Group confirmed it is on track to invest $1.5 billion in artificial intelligence this year. The spend will fund internal efficiency projects and the development of AI‑driven solutions for other insurers and health providers. UnitedHealth aims to embed generative AI...
'It's Just the Beginning' For Pancreatic Cancer's Long-Awaited Breakthrough
Revolution Medicines’ KRAS‑G12D inhibitor daraxonrasib has entered late‑stage trials as a potential first‑in‑class therapy for pancreatic cancer, a disease that still carries a five‑year survival rate below 12%. Early data show tumor shrinkage in roughly a third of heavily pre‑treated...
Carvykti Shows Promise Before Multiple Myeloma; Two Megarounds; AstraZeneca Wins Twice
Researchers at Dana‑Farber Cancer Institute reported that all 20 high‑risk smoldering multiple myeloma patients treated with Carvykti, Janssen's BCMA‑directed CAR‑T therapy, achieved disease clearance. The single‑infusion regimen produced complete responses without immediate relapse, and patients remained progression‑free at a median...
Where Utah’s Experiment with AI Doctors Is Headed Next
Utah has launched a regulatory sandbox that lets AI-driven health platforms prescribe medications under physician oversight, a move that bypasses typical federal restrictions. The state allocated roughly $5 million to attract startups such as Babylon Health and AIMD for pilot programs...
Trump, FDA Plan to Expedite Psychedelic Development
President Donald Trump publicly endorsed psychedelic medicines as a breakthrough for severe mental health disorders, pledging to fast‑track their research and development. The White House announcement coincides with the FDA’s plan to create an accelerated review pathway for psychedelic drug...
Novartis Cuts Two Programs in Cancer-Related Blood Clots
Novartis announced the termination of two late‑stage programs targeting cancer‑related blood clots after a pivotal trial demonstrated inferior efficacy versus existing anticoagulants. The candidates, one of which Novartis out‑licensed in 2019, were being developed to address the high unmet need...
Merck Partner Reveals Bispecific Data; Biogen Pays $100M for Antibody Rights
Merck’s partner Sino Biopharm disclosed first‑in‑human results for its PD‑1×VEGF bispecific antibody, MK‑2010, reporting that six of 11 lung‑cancer patients achieved a response at a low dose. A second cohort showed four responses among nine patients, indicating activity across dosing...
Kelonia Investor Venrock Will Clear a 45-Fold Return on Startup's Sale to Lilly
Venture capital firm Venrock is set to pocket roughly $900 million after its modest $20 million seed investment in Kelonia Therapeutics paid off. Kelonia agreed to an all‑cash acquisition by Eli Lilly valued at $3.25 billion, delivering an upfront payment that triggers the windfall....
Gilead Declines Another Arcus Option After Phase 3 TIGIT Fail
Gilead Sciences has declined another development option with Arcus Biosciences following the Phase 3 failure of their joint TIGIT immunotherapy. The setback ends a key pillar of a long‑standing collaboration and signals Gilead’s intent to trim external programs. Both companies will...
Nektar’s Long-Term Mid-Stage Alopecia Data Fuel Phase 3 Plans
Nektar Therapeutics reported that its IL-2 variant rezpegaldesleukin achieved modest efficacy and safety signals in the long‑term extension of a previously failed Phase 2b alopecia areata trial, barely meeting Wall Street expectations. The data revive confidence in the program and...
Novo Nordisk’s Sickle Cell Therapy Hits in Phase 3, but Data Lag Expectations
Novo Nordisk announced that its oral sickle‑cell drug etavopivat met its primary endpoint in a Phase 3 trial, showing a statistically significant reduction in painful vaso‑occlusive crises. The study, however, fell short of the ambitious efficacy and safety benchmarks the...
Three Gene Therapy Pioneers Just Won the Breakthrough Prize. This Is Their Story
Three pioneering scientists—Jean Bennett, Albert Maguire, and David J. Wilson—have been honored with the 2026 Breakthrough Prize in Life Sciences for their work on Luxturna, the first gene‑therapy approved by the U.S. Food and Drug Administration. Luxturna treats a rare...
New CDC Pick Schwartz Is Praised by Public Health Pros
President Donald Trump nominated Erica Schwartz, a former deputy surgeon general and Coast Guard veteran, to serve as the next CDC director. The appointment comes after a year marked by rapid turnover and uncertainty at the agency’s helm. Schwartz’s résumé...
Kailera IPO Interview: CEO Renaud Talks Biotech Market, China and Obesity Pipeline
Kailera Therapeutics closed a record‑setting $625 million Nasdaq IPO, the largest biotech debut of the year. The company, launched with Bain Capital Life Sciences backing, leverages a portfolio of obesity drug candidates originally sourced from China’s Hengrui Medicine. CEO Renaud highlighted...
#AACR26 Preview: Revolution Medicines, the RAS Bonanza and China ADC Standouts
Revolution Medicines unveiled a pan‑RAS inhibitor that doubled overall survival for patients with recurrent or treatment‑resistant pancreatic cancer. The Phase 2 trial reported a median overall survival of roughly 12 months versus six months with standard chemotherapy. Data were presented at...
Trevi Raises $150M; Spain and Boston Set up Biotech Fund
Trevi Therapeutics priced a $150 million underwritten public offering, bolstering its balance sheet for late‑stage oncology development. The proceeds will primarily fund the advancement of its KRAS‑targeted drug and other pipeline candidates. In parallel, the Spanish government and a Boston‑based venture...
Biovac Gets $108M Backing for Vaccine Factory in South Africa
Biovac announced that its new vaccine manufacturing complex in Cape Town has secured $108 million in financing from the European Investment Bank, the European Commission, and the International Finance Corporation. The plant is designed to produce up to 400 million doses per...
Revolution Medicines' Buyout Price Soars After Pancreatic Cancer Win
Revolution Medicines announced positive Phase 3 data for its pancreatic cancer candidate, showing a statistically significant survival benefit. The breakthrough lifted the company’s market value from roughly $30 billion to an estimated $45 billion, reigniting speculation of a mega‑buyout. Investors rushed in, sending...
Kailera Raises $625M IPO in Biotech Record
Kailera Therapeutics completed a $625 million IPO, establishing a new biotech record and eclipsing Moderna’s 2018 $604 million debut. The offering, led by Goldman Sachs, JPMorgan and Morgan Stanley, attracted strong institutional demand and priced above expectations. Proceeds will fund Kailera’s gene‑editing...
Lilly’s Tirzepatide Sheds Lean Muscle Harder than Novo’s Semaglutide, Study Suggests
A new, pending‑peer‑review study compares Eli Lilly’s tirzepatide with Novo Nordisk’s semaglutide, confirming tirzepatide delivers greater overall weight loss but also leads to a larger reduction in lean body mass. Researchers used dual‑energy X‑ray absorptiometry to quantify fat‑free mass loss, finding up...
RFK Jr. Defends FDA, Makary Following Republican Questions
HHS Secretary Robert F. Kennedy Jr. took the podium before the House Energy & Commerce Committee on April 16, 2026 to defend the Food and Drug Administration and its commissioner, Marty Makary, after a line of Republican inquiries. Kennedy asserted that the FDA’s approval processes remain...
Lilly's Obesity Pill Heads for Diabetes Filing After Heart Risk Trial
Eli Lilly’s newly approved obesity medication, marketed as Foun…, demonstrated a 16% lower incidence of major cardiovascular events compared with a standard insulin regimen in a recent trial. The data, presented by Lilly, suggest the drug not only aids weight loss...
Freya Biosciences Advances Microbial Treatment for IVF Implantation Failure
Freya Biosciences announced that its microbial immunotherapy designed to address IVF implantation failure has progressed to a Phase 2 mid‑stage trial after demonstrating safety and early efficacy in healthy volunteers. The therapy leverages modulation of the uterine microbiome to improve endometrial...
Scribing Startup Abridge Adds NEJM, JAMA as It Moves Into Medical AI Search
Abridge, the AI‑driven clinical scribing startup, has secured licensing deals with the New England Journal of Medicine and the Journal of the American Medical Association. The integration lets physicians pull peer‑reviewed research into their notes in real time, positioning Abridge...
In Vivo Autoimmune CAR-T Race Grows as Two RNA Startups Enter the Clinic
Two RNA‑focused biotech firms have entered human trials of in vivo CAR‑T therapies targeting autoimmune diseases. China’s Immorna reported its first systemic sclerosis patient treated with an RNA‑delivered CAR‑T that reduced peripheral B‑cell activity. A U.S. startup, GeneCure, launched a...
Biogen Filing Reveals Apellis Deal Details; Telix Raises $600M
Biogen disclosed a $5.6 billion acquisition of Apellis, marking a strategic shift from its traditional neurology focus toward broader rare‑disease and complement‑inhibition platforms. The deal, detailed in a recent SEC filing, includes a mix of cash and stock and is expected...
Former FDA Cancer Chief Pazdur Warns of the Political 'Breach' Of Review Teams
Richard Pazdur, who led the FDA’s oncology review program for more than two decades, stepped down in December after only a few weeks as director of the agency’s Center for Drug Evaluation and Research. In his departure, Pazdur warned that...
Revolution Medicines Prices $2B Raise as XBI Reaches Heights Not Seen Since Pandemic
Revolution Medicines priced a $2 billion public offering, marking the biotech sector’s largest equity raise since the COVID‑19 pandemic. The capital raise follows a recent positive readout from the company’s late‑stage trial, boosting investor confidence. The move helped lift the SPDR...
Updated: FDA Asks for Data on Lilly’s Foundayo to Assess Heart, Liver Risks
The U.S. Food and Drug Administration has asked Eli Lilly for additional safety data on its newly approved obesity medication, Foundayo. The agency is specifically seeking information on any cardiovascular events and liver‑related adverse effects observed in clinical trials and post‑marketing...
Replimune Looks Ahead as Repeat CRL Speeds the Company's Decline
Replimune received a second complete response letter (CRL) from the FDA for its lead oncolytic cancer therapy, citing additional data gaps and manufacturing concerns. The regulatory setback triggered a wave of layoffs affecting roughly 30% of its workforce and pushed...
Revolution Medicines Leads Latest Wave of Stock Offerings, Totaling $1.5B
Revolution Medicines anchored a fresh wave of biotech equity offerings on Monday, helping to lift total capital raised to roughly $1.5 billion. The offering round also included Spyre Therapeutics and Allogene Therapeutics, each filing separate share sales. Proceeds are earmarked for...
Endpoints Biopharma Sentiment Survey for Q2 2026
Endpoints Signal is launching its Q2 2026 Biopharma Sentiment Index (BPSI) survey, a three‑minute questionnaire that aggregates insider views into a quarterly benchmark. More than 1,000 biopharma professionals participated in the previous quarter, providing a snapshot of sentiment on pipelines, pricing...
Harbinger Raises $100M; Astellas to Close Seattle Site
Harbinger Health announced a $100 million financing round led by Flagship Pioneering to fast‑track its next‑generation cancer‑detection platform. The capital will fund expanded clinical trials, scale manufacturing, and pursue regulatory clearance for its early‑stage diagnostic test. Harbinger positions its technology as...
J&J Increasingly Confident It Can Manage Stelara Cliff, but Work Remains
Johnson & Johnson says the most intense biosimilar pressure on its blockbuster drug Stelara is largely behind it, and the company now projects robust growth through the late 2020s. Executives cite new therapeutic indications, expanded global reach, and strategic pricing...
Eli Lilly to Pay up to $300M for Cancer Biotech CrossBridge Bio
Eli Lilly announced it will acquire antibody‑drug conjugate (ADC) developer CrossBridge Bio for up to $300 million, combining an upfront cash payment with milestone‑based earn‑outs. CrossBridge, founded by biotech veteran Michael Torres, brings a proprietary ADC platform and a lead oncology candidate currently in...
Parker Institute Doubles Down on Cancer Vaccines as Part of Ongoing Reboot
The Parker Institute for Cancer Immunotherapy announced a renewed focus on mRNA‑based cancer vaccines, launching a multi‑year program that will fund clinical trials and partner with biotech firms. The initiative includes a $200 million investment pool aimed at accelerating vaccine design,...
FDA Approves Travere's Filspari as First Drug for the Kidney Disease FSGS
The U.S. Food and Drug Administration has broadened the label for Travere Therapeutics' drug Filspari, adding a second kidney indication to its approval. Filspari, a dual endothelin‑angiotensin receptor antagonist, was already the first therapy cleared for primary focal segmental glomerulosclerosis...
Click Therapeutics Cuts 27% of Workforce After $50M Raise
Click Therapeutics, a digital therapeutics company, announced a $50 million Series D round led by Boehringer Ingelheim. Within days of the funding, the startup slashed more than a quarter of its workforce, eliminating roughly 27% of employees. The cuts affect both engineering...
FDA Narrows in on Search for New Biologics and Vaccines Leader
The U.S. Food and Drug Administration is close to naming a new director for its Center for Biologics Evaluation and Research (CBER), ending the turbulent tenure of Vinay Prasad. Sources say the leading candidate is Dr. Susan K. Lee, a...
Allogene’s First Cut of Data on ‘Off-the-Shelf’ CAR-T Shows Promise
Allogene Therapeutics reported that its off‑the‑shelf CAR‑T candidate cleared all detectable lymphoma cells in just over half of trial participants. The interim analysis stems from the pivotal ALLO‑501/ALLO‑501A study in relapsed or refractory B‑cell lymphoma. Researchers highlighted a complete molecular...
Neomorph Raises $100M for Molecular Glues; Spyre's Ulcerative Colitis Data
San Diego‑based NeoMorph announced a $100 million financing round to scale its molecular‑glue drug discovery platform. The capital, led by XYZ Ventures and existing biotech backers, will fund preclinical programs aimed at traditionally undruggable targets. In parallel, Spyre Therapeutics disclosed Phase 2...
BioNTech's HER2 ADC Succeeds in Phase 2 Study, FDA Filing Planned
BioNTech announced that its HER2‑targeted antibody‑drug conjugate, trastuzumab pamirtecan (formerly BNT323), achieved robust efficacy in a Phase 2 trial of HER2‑positive metastatic breast cancer. The study reported a 45% overall response rate and a median progression‑free survival of 8.2 months, with...
Ideaya’s Uveal Melanoma Drug Exceeds Success Benchmark in Late-Stage Trial
Ideaya BioSciences reported that its late‑stage drug for uveal melanoma met its pre‑specified success benchmark, achieving a 27% overall response rate versus the 20% target. The trial also demonstrated a manageable safety profile, reinforcing confidence in the therapy’s risk‑benefit balance....
GSK Plans Five Phase 3 Studies for Gynecological Cancer ADC From Hansoh
GlaxoSmithKline (GSK) announced it will initiate five Phase 3 clinical trials to evaluate an antibody‑drug conjugate (ADC) for gynecological cancers, a candidate licensed from Chinese partner Hansoh Pharma. Early-stage data presented on Sunday showed encouraging tumor responses in ovarian and endometrial...
More Pharma Dealmaking; FDA’s Proposed Budget; Takeda Ends Partnership; and More
The pharma sector is seeing a wave of dealmaking, with Q1 2026 M&A volume up roughly 15% as companies chase high‑value oncology assets. The FDA released a proposed $5.6 billion budget that would raise review fees by about 8% and modestly...
Plan for Remade ACIP Panel Adds Focus on Vaccine Safety, Matching Kennedy’s Push
A federal judge recently halted most Trump-era appointments to the CDC’s Advisory Committee on Immunization Practices (ACIP), prompting the agency to draft a new charter that reshapes the panel’s composition and priorities. The revised charter emphasizes vaccine safety, mandating transparent...
Bayer Pharma Executive Predicts US-Europe Price Spreads Will Narrow
Bayer's chief operating officer for pharmaceuticals warned that the long‑standing price gap between the United States and European markets will shrink sharply. He attributes the change to the Trump administration's push for “most‑favored‑nation” (MFN) pricing agreements, which compel manufacturers to...
China Biotech’s CRISPR Therapy Suggests US Drugmakers Will Face Competition
A Chinese biotech firm used CRISPR‑Cas9 to edit blood stem cells in five beta thalassemia patients, eliminating their need for regular transfusions. The ex‑vivo therapy reactivates fetal hemoglobin and showed durable engraftment with no serious adverse events over a year...
Vivatides Gets $54M; Wegovy Drops Cold Chain in EU; Gilead Takes Kymera Option
Vivatides Therapeutics announced a $54 million Series A round to accelerate its pre‑clinical siRNA and antisense oligonucleotide programs, with Sequoia Capital leading the investment. In Europe, Novo Nordisk confirmed that its obesity drug Wegovy will drop the costly cold‑chain requirement, simplifying distribution. Meanwhile,...